Tagged with J&J

Singapore J&J Singapore’s Guillermo Frydman outlines how his affiliate negotiated the COVID-19 pandemic; why managing J&J’s pharma, medical devices, vision care and consumer businesses together offers unique opportunities to engage as a ‘broad healthcare company’; and Singapore’s role as an innovation hub for the region.   There are many learnings on…

Global The Top 20 companies on the 2021 Access to Medicines Index ranked on governance of access, research and development, and product delivery indices. Compiled by the Access to Medicine Foundation, the report measures how well the largest 20 global Big Pharma companies are making drugs and vaccines accessible to low-…

Norway Filip Standaert outlines the significance of the Nordic cluster to J&J’s medical device operations in Europe, how the affiliate responded to the COVID-19 crisis, and the ways in which J&J is aiming to contribute to driving efficiencies within the Norwegian healthcare system.   There is still change management to be…

South Africa South African firm Aspen has inked a deal with Johnson & Johnson for the technical transfer and proposed commercial manufacture of their COVID-19 vaccine candidate, Ad26.COV2-S, boosting the company’s share price as well as its global profile.   Aspen is best known internationally for bringing generic antiretrovirals for HIV to…

Roundup A roundup of the latest news from Spanish pharma, including J&J’s COVID-19 vaccine trial, the latest developments at Spanish firm PharmaMar which hopes its Aplidin can be used as a treatment for COVID-19, and a new biologics plant for contract manufacturer LSNE in the city of León.   Johnson &…

M&A In the wake of Sanofi’s USD 3.7 billion tie-up for US biotech Principia, J&J has moved to bolster its autoimmune portfolio with the acquisition of Momenta Pharmaceuticals for USD 6.5 billion, a further signal of Big Pharma’s prioritisation of rare disease treatments.   The all-cash deal sees J&J’s pharmaceutical division…

China Johnson & Johnson’s network of healthcare innovation incubators, JLABS, opened its doors in Shanghai in June 2019 and now stands as the largest such institution of 13 globally. JLABS @ Shanghai’s head, Dr Sharon Chan, recently sat down with PharmaBoardroom to explain the JLABS model, how it has had to…

Coronavirus During the 28 May 2020 IFPMA media briefing on COVID-19 vaccines, four of the pharmaceutical industry’s leading executives discussed where their firms are in the race to find a vaccine, the unprecedented levels of speed and collaboration being seen, and the challenges that lie ahead. Here we present five of…

China Dr Sharon Chan, head of JLABS @ Shanghai – the first JLABS presence in Asia-Pacific as well as the largest globally – shares how Johnson & Johnson is investing in the innovation ecosystem in China and the APAC region; some of the key milestones over the past year; and her…

Mexico A compilation of the top 10 pharmaceutical companies in the Mexican pharmaceutical market based on IQVIA data from February MAT 2020. Four of the top ten companies are Mexican: PISA, Sanfer, Senosiain and Siegfried Rhein.   1. Sanofi Global CEO: Paul Hudson Country Chair: Fernando Sampaio Sanofi has had a…

Medtech Key stakeholders within the Czech medtech industry highlight how medical devices can improve efficiency and quality of care across the country’s healthcare landscape, why greater levels of collaboration are of vital importance to achieving this, and how the Czech Republic stands out in the CEE region for its uptake of…

Coronavirus The CEOs and top executives, David Ricks, chairman and CEO, Eli Lilly & Co and IFPMA president, Severin Schwan, CEO, Roche, Paul Stoffels, chief scientific officer, Johnson & Johnson, David Loew, executive VP, Sanofi Pasteur and Rajeev Venkayya, president, Global Vaccines Business Unit, Takeda took part in a virtual press…